Skip to main content

Table 2 Respondents’ general knowledge on the safety of conventional synthetic disease modifying anti-rheumatic drugs, biologics/small molecules, and other medications in the management of inflammatory arthritis in pregnancy

From: Management of Inflammatory Arthritis in pregnancy: a National Cross-Sectional Survey of Canadian rheumatologists

  Safe throughout pregnancy (% of respondents) Safe during certain trimesters (% of respondents) Not safe at all (% of respondents) Not sure (% of respondents)
Conventional synthetic disease modifying anti-rheumatic drugs
 Azathioprine 80.5* 4.9 12.2 2.4
 Chloroquine 74.1 1.2 8.6 16.0
 Cyclophosphamide 0 3.7 95.1* 1.2
 Cyclosporine 28.0 6.1 42.7 23.2
 Doxycycline 2.4 4.9 59.8 32.9
 Gold salts 28.7 2.5 33.8 35.0
 Hydroxychloroquine 92.7* 4.9 1.2 1.2
 Leflunomide 0 0 97.6* 2.4
 Methotrexate 0 1.2 97.6* 1.2
 Minocycline 0 4.9 53.1 42.0
 Mycophenolate mofetil 2.5 2.5 81.5* 13.6
 Sulfasalazine 70.4 8.6 18.5 2.5
Biologics/small molecules
 Abatacept 9.8 9.8 15.9 64.6
 Adalimumab 37.0 32.1 6.2 24.7
 Anakinra 9.9 6.2 16.0 67.9
 Apremilast 0 1.2 18.5 80.2*
 Certolizumab 61.0 15.9 4.9 18.3
 Etanercept 43.9 29.3 7.3 19.5
 Golimumab 37.8 25.6 11.0 25.6
 Infliximab 37.8 30.5 8.5 23.2
 Rituximab 8.5 8.5 25.6 57.3
 Tocilizumab 11.0 8.5 19.5 61.0
 Tofacitinib 1.2 1.2 21.0 76.5*
 Ustekinumab 4.9 6.1 18.3 70.7
Other medications
 Celecoxib 0 54.9 29.3 15.9
 Ibuprofen 1.2 83.6* 14.5 1.2
 Naproxen 2.4 82.9* 11.0 3.7
 Other NSAIDs 1.2 67.5 22.5 8.8
  1. *Indicates consensus among respondents based on a priori cut-off of ≥75%